(RTTNews) - Ultragenyx Pharmaceutical Inc. (RARE) announced Phase 1/2 data in support of the Phase 3 Aspire study for GTX-102, its investigational antisense oligonucleotide for Angelman syndrome.
New York Sirens Professional Womens Hockey League November 7, 2024 New York Sirens Professional Womens Hockey League November 7, 2024 Montreal Victoire Professional Womens Hockey League November 7, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback
